OR WAIT null SECS
August 03, 2021
FDA will be asked to consider ONS-5010 for treating wet AMD.
August 02, 2021
If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.
New opportunities continue to develop in an evolving landscape.
July 30, 2021
With orphan drug and fast track status, Neurotech plans to seek FDA approval for its NT-501 Implant platform late next year.
July 29, 2021
Investigators have found that 78% of neovascular AMD cases have been detected using the PHP home monitoring system.
July 28, 2021
A team of investigators used corneal confocal microscopy to identify corneal nerve damage in cases of long COVID-19.
July 27, 2021
The American Society of Cataract and Refractive Surgery hosted its 2021 ASCRS and ASOA Annual Meeting July 23-27 in Las Vegas, Nevada.
July 26, 2021
Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.
July 23, 2021
Mark Breazzano, MD, discusses the effects of the COVID-19 pandemic on daily practice for retina specialists.
July 22, 2021
A team of investigators found that the retina may offer signs of COVID-19 infection before symptoms present.
